

Practitioner's Docket No. MPI97-035CP1M**LISTING OF THE CLAIMS:**

Kindly cancel claims 2-4, 15, 16, 46, 47, 50, 58, and 59; amend claim 6, claim 7, claim 10, claim 45, claim 49, claim 53, claim 55, and claim 57 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

STATUS OF THE CLAIMS:

1. cancelled
2. cancelled
3. cancelled.
4. cancelled
5. cancelled
6. (currently amended) The isolated polypeptide of claim 7-4, which is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1, with a mutation resulting in a variant where at least one of His374, His 378, and His417 are any amino acid other than histidine.
7. (currently amended) ~~The isolated polypeptide of claim 6,~~ An isolated polypeptide which has at least one bioactivity of an ACE-2 polypeptide which has the amino acid sequence set forth in SEQ ID NO: 2 with a mutation resulting in a variant where at least one of His374, His 378, and His417 are any amino acid other than histidine.
8. cancelled
9. cancelled
10. (currently amended) The isolated polypeptide of claim ~~16,7~~, which binds an ACE-2 target peptide.
11. (previously presented) The isolated polypeptide of claim 10, which binds angiotensin I.
12. (previously presented) The isolated polypeptide of claim 11, which lacks the ability to hydrolyze angiotensin I into angiotensin (1-9).
13. (previously presented) The isolated polypeptide of claim 10, which binds kinetensin.

Practitioner's Docket No. MPI97-035CP1M

14. (previously presented) The isolated polypeptide of claim 13, which lacks the ability to hydrolyze kinetensin into kinetensin (1-8).

15. (cancelled)

16. (cancelled)

17-43 cancelled.

44. cancelled

45. (currently amended) An isolated polypeptide which has at least one bioactivity of an ACE-2 polypeptide comprising ~~an amino acid sequence having an amino acid identity of at least 90% with the~~ entire amino acid sequence set forth in SEQ ID NO: 2, wherein at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.

46. cancelled.

47. cancelled.

48. cancelled

49. (currently amended) The isolated polypeptide of claim 47, 45, which is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1, with a mutation resulting in a variant where at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.

50. cancelled

51. cancelled

52. cancelled

53. (currently amended) The isolated polypeptide of claim ~~59~~, 45, which binds an ACE-2 target peptide.

54. (previously presented) The isolated polypeptide of claim 53, which binds angiotensin I.

55. (currently amended) The isolated polypeptide of claim 59, 54, which lacks the ability to hydrolyze angiotensin I into angiotensin (1-9).

56. (previously presented) The isolated polypeptide of claim 53, which binds kinetensin.

Practitioner's Docket No. MPI97-035CP1M

57. (currently amended) The isolated polypeptide of claim ~~59~~, 56, which lacks the ability to hydrolyze kinetensin into kinctensin (1-8).

58. cancelled

59. cancelled

60 cancelled

(Page 4 of 6)